Compare Stocks → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALBONASDAQ:CNCENASDAQ:EOLSNASDAQ:LXRXNASDAQ:SPPI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15-0.2%$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AEOLSEvolus$11.72+1.6%$13.55$7.07▼$15.43$679.06M1.45621,920 shs339,146 shsLXRXLexicon Pharmaceuticals$1.71+3.6%$2.34$0.92▼$3.79$421.07M1.274.46 million shs4.08 million shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/A7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%EOLSEvolus+1.65%-1.43%-15.13%-0.26%+28.09%LXRXLexicon Pharmaceuticals+3.64%-8.56%-24.34%+6.87%-31.33%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%+46.85%SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBOAlbireo PharmaN/AN/AN/AN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AEOLSEvolus4.1192 of 5 stars3.53.00.03.52.72.50.6LXRXLexicon Pharmaceuticals0.838 of 5 stars3.01.00.00.01.31.70.6SPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBOAlbireo PharmaN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AEOLSEvolus3.00Buy$20.6075.77% UpsideLXRXLexicon Pharmaceuticals2.00Hold$5.00192.40% UpsideSPPISpectrum Pharmaceuticals2.00HoldN/AN/ACurrent Analyst RatingsLatest ALBO, SPPI, LXRX, CNCE, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/10/2024EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.003/1/2024EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.001/29/2024EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$10.00 ➝ $16.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58EOLSEvolus$202.09M3.36N/AN/A($0.36) per share-32.56LXRXLexicon Pharmaceuticals$1.20M350.89N/AN/A$0.38 per share4.50SPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/ACNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AEOLSEvolus-$61.69M-$1.09N/AN/AN/A-30.52%N/A-32.19%5/14/2024 (Estimated)LXRXLexicon Pharmaceuticals-$177.12M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest ALBO, SPPI, LXRX, CNCE, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023LXRXLexicon Pharmaceuticals-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million3/7/2024Q4 2023EOLSEvolus-$0.15-$0.20-$0.05-$0.19$61.14 million$61.00 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBOAlbireo PharmaN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBOAlbireo PharmaN/A6.326.23CNCEConcert PharmaceuticalsN/A9.039.03EOLSEvolusN/A2.332.10LXRXLexicon Pharmaceuticals1.075.605.58SPPISpectrum PharmaceuticalsN/A2.712.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBOAlbireo Pharma94.25%CNCEConcert Pharmaceuticals70.63%EOLSEvolus90.69%LXRXLexicon Pharmaceuticals74.70%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipALBOAlbireo Pharma6.90%CNCEConcert Pharmaceuticals11.33%EOLSEvolus5.40%LXRXLexicon Pharmaceuticals4.50%SPPISpectrum Pharmaceuticals2.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableEOLSEvolus27357.94 million54.82 millionOptionableLXRXLexicon Pharmaceuticals285246.24 million235.16 millionOptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableALBO, SPPI, LXRX, CNCE, and EOLS HeadlinesSourceHeadlineAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTmarkets.businessinsider.com - February 21 at 11:54 PMLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinemarkets.businessinsider.com - February 21 at 1:34 PMLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinskymarkets.businessinsider.com - February 8 at 2:32 PMAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 5 at 2:12 PMGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)stockhouse.com - February 1 at 1:26 PMCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class Actionmarkets.businessinsider.com - February 1 at 1:16 AMSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming Deadlinestockhouse.com - January 30 at 10:18 AMINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) Investorstmcnet.com - January 26 at 6:41 PMLobbying revenues continued climbing amid stalled Hill actionpolitico.com - January 23 at 7:48 PMINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming Deadlinestockhouse.com - January 13 at 10:52 PMEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 12 at 6:07 AMVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen Researchfinance.yahoo.com - January 10 at 10:13 AMSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) Investorsmsn.com - January 9 at 8:33 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTmarkets.businessinsider.com - November 9 at 7:46 PM$19.30+ Bn Neutropenia Treatment Market to Grow at 5.4% CAGR, Globally, by 2027pharmiweb.com - November 8 at 7:16 PMDisney offers streaming service discount amid Spectrum blackoutctpost.com - September 8 at 6:23 PMAnalyzing Spectrum Pharmaceuticals Inc. (SPPI) After Recent Trading Activityknoxdaily.com - July 31 at 5:06 PMSpectrum Pharmaceuticals Inc. [SPPI] CFO makes an insider sale of 32,387 shares worth 35,496.knoxdaily.com - July 28 at 10:55 AMBuy Spectrum Pharmaceuticals For Exposure To Assertio Holdingsseekingalpha.com - July 24 at 6:02 AMPotential Price Increase for Spectrum Pharmaceuticals Inc. (SPPI) After Recent Insider Activityknoxdaily.com - July 19 at 7:14 PMNegative sentiment towards SPPI reflected by a jump of 6.23% in short interestknoxdaily.com - July 14 at 9:14 PMSpectrum Pharmaceuticals Inc. [SPPI] Investment Appeal on the Riseknoxdaily.com - July 11 at 7:15 PMSpectrum Pharmaceuticals (NASDAQ: SPPI)fool.com - July 8 at 8:10 PMSelling Buzz: Spectrum Pharmaceuticals Inc. [SPPI] CFO Brennan Nora sells 32,387 shares of the companyknoxdaily.com - July 6 at 3:12 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAlbireo PharmaNASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.EvolusNASDAQ:EOLSEvolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Spectrum PharmaceuticalsNASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.